hsa-miR-25

ncRNA information

ncRNA name

hsa-miR-25

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

FOXO3

Cancer information

Cancer name

Gastric Cancer

Cancer site

Stomach

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Overexpression of miR-25 significantly enhanced cell cycle progression and decreased the sensitivity of SGC-7901 cells to cisplatin.

Tissue resource

human gastric cancer cell lines SGC-7901

human gastric cancer cisplatin-resistant cell lines SGC-7901/DDP

Experiment

qRT-PCR,Western blot


Institute

Nanjing KeyGen Biotech Co., Ltd.

Country

China

Continent

Asia